Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy

Manuscript Number: 

19-1254R2

Author(s): 
Gareth Ambler, Gargi Banerjee, John C. Dickson, Martha S. Foiani, Nick C. Fox, Francesco Fraioli, Ashley M. Groves, Amanda Heslegrave, Ashvini Keshavan, Michael P. Lunn, Ross W. Paterson, Jonathan M. Schott, Jamie Toombs, David J. Werring, Henrik Zetterberg

Disclosures

Gareth Ambler

  • Nothing to Disclose

Gargi Banerjee

  • Nothing to Disclose

John C. Dickson

  • Consulting Fees:
    Consultant for GE Healthcare in support of multi-centre trials (<£1000) Consultant for Biogen in support of multi-centre trials (<£2000) Consultant for Bioclinica in support of multi-centre trials (<£2000).
    Lecture Fees:
    Lecture fees on quantitative imaging (<£2000).

Martha S. Foiani

  • Nothing to Disclose

Nick C. Fox

  • Consulting Fees:
    I have served on advisory boards for Roche (all fees paid to my Institution) I also serve on a data safety monitoring board for Biogen

Francesco Fraioli

  • Nothing to Disclose

Ashley M. Groves

  • Nothing to Disclose

Amanda Heslegrave

  • Nothing to Disclose

Ashvini Keshavan

  • Nothing to Disclose

Michael P. Lunn

  • Nothing to Disclose

Ross W. Paterson

  • Nothing to Disclose

Jonathan M. Schott

  • Consulting Fees:
    I have served on advisory boards for Roche, Eli Lilly, Biogen, Merck and GE
    Lecture Fees:
    I have given education lectures sponsored by Eli Lilly, Biogen and GE
    Patents/Royalties
    I receive royalties from Henry Stewart Talks and Oxford University Press. I am Chief Medical Office for Alzheimer's Research UK
    Grants
    • Agency: 
      Avid Radiopharmaceuticals (Eli Lilly) -- radiotraqcer provision
      Dates: 
      2005 -

David J. Werring

  • Consulting Fees:
    DJW has received honoraria for chairing, speaking and advisory boards from Bayer, and for an advisory board from Alnylam.

Henrik Zetterberg

  • Consulting Fees:
    HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx (not related to this study).
    Equity:
    HZ is one of the founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (not related to this study).

Jamie Toombs

  • Disclosure not yet completed